From: Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study
Cohort description | Univariate risk analysis | ||||||
---|---|---|---|---|---|---|---|
Patients’ features | Distribution | N. of events | Person-days at risk | Rate (95%CI) | RR (95%CI) | p-value | |
Sex | Male | 65 (57.52%) | 121 | 32675 | 3.70 (2.71-5.19) | 1.00 | Â |
Female | 48 (42.48%) | 60 | 22248 | 2.70 (1.71-4.50) | 0.73 (0.38-1.40) | 0.342 | |
Age | <60 | 60 (53.10%) | 127 | 29824 | 4.26 (3.16-5.86) | 1.00 | Â |
60 or more | 53 (47.90%) | 54 | 25099 | 2.15 (1.33-3.70) | 0.49 (0.26-0.93) | 0.028 | |
Nadir A | ≥ 0.13 ×109 /L | 85 (75.22%) | 104 | 41183 | 2.53 (1.82-3.59) | 1.00 |  |
<0.13 Ă—109 /L | 28 (24.78%) | 77 | 1374 | 5.60 (3.83-8.51) | 2.04 (1.02-4.05) | 0.042 | |
GVHD | No | 98 (86.73%) | 141 | 47756 | 2.95 (2.20-4.06) | 1.00 | Â |
Yes | 15 (13.27%) | 40 | 7167 | 5.58 (3.38-9.79) | 2.18 (0.88-5.44) | 0.090 | |
HIV | Neg | 103 (91.15%) | 153 | 50914 | 3.01 (2.28-4.05) | 1.00 | Â |
Pos | 10 (8.85%) | 28 | 4009 | 6.98 (3.45-15.35) | 3.13 (1.06-9.24) | 0.039 | |
Relapse | No | 93 (82.30%) | 138 | 45537 | 3.03 (2.27-4.13) | 1.00 | Â |
Yes | 20 (17.70%) | 43 | 9386 | 4.58 (2.56-8.92) | 1.81 (0.79-4.15) | 0.163 | |
Protocol | R alone | 20 (17.70%) | 25 | 10362 | 2.41 (1.26-5.26) | 1.00 | Â |
R and CHT | 56 (49.56%) | 69 | 25417 | 2.71 (1.76-4.37) | 1.60 (0.68-3.77) | Â | |
R and auto HSCT | 10 (8.85%) | 11 | 545 | 2.02 (0.69-8.49) | 0.84 (0.24-2.93) | Â | |
R and allo HSCT | 27 (23.89%) | 76 | 13694 | 5.55 (3.85-8.27) | 2.73 (1.08-6.94) | 0.102 | |
Disease | Indolent lymph. B | 43 (38.05%) | 45 | 21934 | 2.05 (1.28-3.50) | 1.00 | Â |
Aggressive lymph. C | 53 (46.90%) | 97 | 25188 | 3.85 (2.67-5.72) | 2.31 (1.18-4.54) | Â | |
Non-CD20 malig. D | 17 (15.05%) | 39 | 7801 | 5.00 (2.92-9.23) | 2.95 (1.16-7.53) | 0.024 | |
Time | 1st semester | 113 E | 108 | 18999 | 5.68 (4.20-7.89) | 1.00 | <0.001 |
2nd semester | 99 E | 40 | 18018 | 2.22 (1.43-3.65) | 0.43 (0.30-0.63) | ||
3rd semester | 99 E | 33 | 17906 | 1.84 (1.08-3.41) | 0.36 (0.24-0.53) | ||
Median R doses (iqr) | 4 (2–6) | - | - | - | 0.95 (0.84-1.08) | 0.471 | |
Mean days between doses (iqr) | 17 (9–19) | - | - | - | 0.99 (0.97-1.02) | 0.664 | |
Median days with <1000 ly (iqr) | 38 (0–220) | - | - | - | 1.00 (1.00-1.00) | 0.946 | |
Overall | 113 (100%) | 181 | 54923 | 3.30 (2.54-4.34) | Â | Â |